Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Bivamelagon · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Bivamelagon (open-label) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Bivamelagon | DRUG | daily dose of oral bivamelagon |
Key Inclusion Criteria: * Completed LG-MCCL005 and participant demonstrated adequate safety and tolerability in that study as determined by the Investigator. * Agree to use a highly effective form of contraception and follow contraception requirements throughout the study and for 90 days after. Ke...
Bivamelagon is an investigational small molecule being developed for the treatment of hypothalamic obesity, a form of obesity that results from damage to the hypothalamus. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Bivamelagon is being developed by Rhythm Pharmaceuticals, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol RYTM. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with hypothalamic obesity.
Bivamelagon is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval and is still being studied in clinical trials to assess its potential as a treatment for hypothalamic obesity.
Bivamelagon is being studied in a Phase 2 clinical trial with the identifier NCT07156578. This long-term study is enrolling participants with hypothalamic obesity by invitation and aims to include 25 participants in the United States and United Kingdom.
No alternative names for Bivamelagon have been disclosed. It is identified solely by its generic name, Bivamelagon, in clinical trial registries and by its developer, Rhythm Pharmaceuticals.